SEC Form 4 · accession 0001209191-16-108961
Kite Pharma, Inc. · KITE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Timothy L. Moore
Officer — EVP, Technical Operations
Period of report
Mar 15, 2016
Accepted (ET)
Mar 16, 2016 · 8:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001510580
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 15, 2016 | A | 50,000 | $0.00 | A | 50,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $44.91 | Mar 15, 2016 | A | 155,000 | A | — | Mar 14, 2026 | Common Stock | 155,000 | 155,000 | D |
| Employee Stock Option (Right to Buy) | $44.91 | Mar 15, 2016 | A | 75,000 | A | Mar 15, 2018 | Mar 14, 2026 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F125% of the shares subject to the stock option vest and become exercisable on the first anniversary of the grant date identified in column 3, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.